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Abstract
Background: The growth arrest-specific transcript 5 gene (GAS5) encodes a long noncoding RNA (lncRNA) and hosts a
number of small nucleolar RNAs (snoRNAs) that have recently been implicated in multiple cellular processes and cancer.
Here, we investigate the relationship between DNA damage, p53, and the GAS5 snoRNAs to gain further insight into the
potential role of this locus in cell survival and oncogenesis both in vivo and in vitro.
Methods: We used quantitative techniques to analyse the effect of DNA damage on GAS5 snoRNA expression and to assess
the relationship between p53 and the GAS5 snoRNAs in cancer cell lines and in normal, pre-malignant, and malignant
human colorectal tissue and used biological techniques to suggest potential roles for these snoRNAs in the DNA damage
response.
Results: GAS5-derived snoRNA expression was induced by DNA damage in a p53-dependent manner in colorectal cancer
cell lines and their levels were not affected by DICER. Furthermore, p53 levels strongly correlated with GAS5-derived snoRNA
expression in colorectal tissue.
Conclusions: In aggregate, these data suggest that the GAS5-derived snoRNAs are under control of p53 and that they have
an important role in mediating the p53 response to DNA damage, which may not relate to their function in the ribosome.
We suggest that these snoRNAs are not processed by DICER to form smaller snoRNA-derived RNAs with microRNA (miRNA)-
like functions, but their precise role requires further evaluation. Furthermore, since GAS5 host snoRNAs are often used as
endogenous controls in qPCR quantifications we show that their use as housekeeping genes in DNA damage experiments
can lead to inaccurate results.
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Introduction
snoRNAs are a well-characterized class of ubiquitously
expressed, non-coding RNAs (ncRNAs) that are 60–300 nucleo-
tides in length [1]. Predominantly located in the nucleolus they
classically function as guide RNAs for the post-transcriptional
maturation and modification of ribosomal RNAs (rRNAs) and
snRNAs involved in the spliceosome. snoRNA guide sequences
hybridize specifically to their rRNA target sequence, and, via
associations with proteins, form small nucleolar ribonucleoprotein
complexes (snoRNPs) and execute specific rRNA modifications
[1]. Therefore, snoRNAs are crucial for ribosomal function and
the effective regulation of translation and thus, unsurprisingly, are
highly conserved throughout evolution [2]. There are two major
classes of snoRNAs, termed C/D box snoRNAs and H/ACA box
snoRNAs, respectively. They differ in terms of their sequence and
structure, their binding partners and the nature of the post-
transcriptional modifications that they induce [2,3].
In eukaryotic genomes, snoRNAs are predominantly encoded in
the introns of protein-coding host genes but some are under the
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control of independent promoters [4]. In humans, most snoRNAs
are intronic and co-transcribed with their host gene transcripts,
and then processed out of the excised introns [5]. However, the
transcription of a minority occurs through independent RNA
polymerase II or III activity in a similar manner to many miRNAs
[5,6]. Closely related snoRNA family members are usually
encoded in different introns of the same host gene, but some host
genes encode numerous unrelated snoRNAs. Although some
snoRNA host genes appear to be non-protein coding, many are
involved in nucleolar function and protein synthesis, and as such
there is often an element of co-functioning [5,7]. The fact that in
humans, most snoRNAs are encoded in the introns of protein-
coding and non-protein-coding genes gave rise to the assumption
that these host genes act solely as cellular housekeepers via their
snoRNA-encoding sequences [8,9]. However, recent studies have
challenged this concept and have implicated snoRNAs and their
host genes in the control of oncogenesis and cell fate [10,11]. The
existence of a number of ‘orphan’ snoRNAs with no known rRNA
targets, and the demonstration of their presence in subcellular
locations other than the nucleolus [12], supports the concept that
this group of small non-coding RNAs may regulate other
molecules and have additional cellular functions [13]. Further-
more, a number of studies suggest an evolutionary relationship
between miRNAs and snoRNAs [14] and others report that
mature snoRNAs may undergo further cellular processing to form
smaller snoRNA-derived RNAs (sdRNAs) with miRNA-like
functions [3,14–17]. Additionally, snoRNA expression has been
shown to be as variable as miRNA expression in human tumour
samples and normalising miRNA polymerase chain reaction
(PCR) expression data to these snoRNAs introduced bias in
associations between miRNA and outcome [18].
The growth arrest-specific transcript 5 gene (GAS5), located at 1q25,
is a non-protein-coding multiple snoRNA host gene comprising of
12 exons [19,20] initially discovered during screening for potential
tumor suppressor genes expressed at high levels during growth
arrest. In humans, it encodes ten intronic C/D box snoRNAs and
two mature long non-coding RNAs (lncRNAs) isoforms that
originate from alternative 59-splice donor sites in exon 7 [20]. The
open reading frame encoded within GAS5 exons is short and is not
thought to encode a functional protein. Mapping of its 5* end
demonstrates that it possesses an oligopyrimidine tract character-
istic of the 5*-terminal oligopyrimidine (5*TOP) class of genes that
accumulate during cell cycle arrest but are rapidly degraded by
nonsense-mediated decay during cell growth. The classification of
GAS5 as a 5*TOP gene offers an explanation as to why it is a
growth arrest specific transcript as while the spliced GAS5 RNA is
normally associated with ribosomes and rapidly degraded, during
arrested cell growth it accumulates in mRNP particles. Interest-
ingly, the only regions of conservation between mouse and human
GAS5 genes are their snoRNAs and 5*-end sequences [20]
suggesting that these are the most important functional compo-
nents. Although GAS5 plays a role in post-transcriptional
modification of ribosomal RNA through its snoRNAs, a number
of recent studies have implicated this gene in other important
cellular processes [10,18,21,22]. The GAS5 lncRNA was shown to
interact with the DNA-binding domain of the glucocorticoid
receptor where it acts as a riborepressor, influencing cell survival
and metabolic activities during starvation by modulating the
transcriptional activity of this receptor [10]. Furthermore, the
same group showed in prostate cell lines, that GAS5 mRNA
sequesters the androgen/androgen receptor complex and prevents
its binding to target DNA sequences [10], which is likely to play an
important role in modulating the effects of androgens in the
prostate. GAS5 transcripts have also been shown to be important
regulators of cell survival and apoptosis in human T-cells and
breast and prostate cancer cell lines [21–23], and their overex-
pression sensitized mammalian cancer cell lines to inducers of
apoptosis [21]. Furthermore, reduced expression of GAS5 and/or
its snoRNAs has been demonstrated in head and neck squamous
cell carcinoma [18], breast cancer [18,21] and glioblastoma
multiforme [24], whilst over-expression of U44, U76 and U78 has
been shown in NSCLC [25]. The aberrant GAS5 expression
demonstrated in breast and head and neck cancer was associated
with poor prognosis [18].
Despite these data, little is known as to the precise role of
specific GAS5 snoRNAs in the pathways in which they have been
implicated, and even less is accepted about the mechanisms
underlying them. Given the previously described role of GAS5 in
the regulation of apoptosis and the well documented role for p53
in the same process, we aimed to further investigate the
relationship between p53 and the GAS5 snoRNAs to gain further
insight into their potential role in cell survival and oncogenesis in
colorectal cancer both in vivo and in vitro. In addition we
demonstrated that both U44 and U47 GAS5 derived snoRNAs,
that are amongst the commonest snoRNAs used as housekeeping
genes for normalization in association with taqman miRNA
expression analysis and should be avoided in DNA damage
experiments.
Materials and Methods
Ethics Statement
Ethical approval was obtained from Imperial College’s ethical
review board. The study was performed in accordance with the
Declaration of Helsinki and written informed consent was
obtained from all patients prior to obtaining tissue samples for
the purpose of the study.
Collection, handling and RNA extraction from laser
captured micro-dissected (LCM) tumour samples
With the approval of our institutional review board, tissue
specimens representing normal colonic tissue and colonic adeno-
carcinoma were obtained immediately after surgery, cut into
blocks, and then formalin fixed and embedded in paraffin. Written
informed consent was obtained. Prior to microdissection, eight 8-
mm serial sections were cut (225uC) from the same tissue block
and placed onto slides (1 mm), that were then deparaffinized
stained with Hematoxylin and Eosin. They were then microdis-
sected using the PALM Laser MicroBeam system (P.A.L.M.
Microlaser Technologies GmbH, Bernried, Germany). A total
area of 200,000 mm2 was micro-dissected from each slide. Figure 1
shows images of various stages of the microdissection process.
RNA was then extracted from the micro-dissected samples the
RNeasy MinElute RNA Isolation Kit (Qiagen, Courtaboeuf,
France).
Collection, handling and RNA extraction from macro-
dissected colorectal tissue
We wished to investigate whether a relationship existed between
p53 activity and the expression of GAS5-snoRNAs in human
colorectal tissue, and in particular in colorectal tumour samples.
We collected paired samples of fresh frozen colorectal tumour
tissue and corresponding normal colorectal tissue from 20
individual patients and measured miR-34a and snoRNA levels
and p53 expression in these samples. Specimens of normal,
adenomatous and malignant colorectal tissue were obtained from
individuals undergoing colorectal surgery or colonoscopy between
The Relationship between p53 and GAS5 snoRNAs
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2011 and 2013 at St Mary’s Hospital, London, UK. Written
informed consent was obtained from each patient. Samples were
immediately macrodissected at the time of surgery, placed directly
in RNALater stabilization solution (Qiagen, Hilden, Germany),
stored at room temperature for 2–3 hours, and then frozen at
280uC. H&E staining was used for histological confirmation of
cancer and to determine the cellularity of representative sections.
A specialist colorectal pathologist reviewed the slides, and tissue for
RNA isolation was verified to contain $60% neoplastic cells.
Written informed consent was obtained from all patients, and
ethical approval was provided by the hospital’s research ethics
committee. Fresh tissue stored in RNALater (Qiagen) was crushed
in liquid nitrogen and the subsequent powder lysed in Trizol
(Invitrogen, Paisley, UK) reagent and RNA isolation was carried
out according to manufacturer’s instructions.
Cell culture and doxorubicin treatment
p53 wild-type (WT) and knockout (KO) HCT116 cells and
DICER WT and knockdown (KD) cell lines were kindly supplied
by Dr. Bert Volgestein [26,27]. Cells were plated in 150 mm
dishes at a 50% confluence and incubated under at 37uC in a
humidified 5% CO2 incubator. They were then treated with
doxorubicin at a concentration of 0.2 ug/ml or equivalent volume
of vehicle (ddh20). After each treatment time point, dishes were
placed on ice and medium was aspirated. Cells were washed twice
with cold PBS, scraped and centrifuged for 5 minutes at
1300 rpm. The supernatant was removed and the cell pellet was
processed for RNA using Trizol reagent (Invitrogen, Paisley, UK)
and/or protein extraction.
RNA quantification and RT-qPCR Analysis
Quantification of extracted RNA was performed using the
NanoDrop ND-1000 spectrophotometer (Thermo Scientific, USA)
and its quality was analyzed using the RNA 6000 Pico LabChip kit
and the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA) or via non-denaturing agarose gel electrophoresis. Total
RNA (10 ng) was reverse transcribed into cDNA using the
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosys-
tems) using a primer specific to each mature miRNA, snoRNA or
snRNA. U6 and U19 (small nucleolar RNA) was used as
endogenous controls for normalization as previously described
[28]. qRT-PCR was performed using the TaqMan MicroRNA
assaykit (Applied Biosystems). The reaction mix consisted of 10 ml
of TaqMan universal master mix 2x, 1 ml of TaqMan mix 20x,
1 ng of cDNA in a final volume of 20 ml. Quantitative real-time
PCR (qPCR) was performed with an ABI Prism 7900HT
sequence detection system (Applied Biosystems). Data were
analysed using qBasePlus software (biogazelle). Levels shown are
means of three independent cDNA replications. Normalisation
was performed using the delta Ct method.
SDS-polyacrylamide gel electrophoresis and western blot
Cell pellets or fresh frozen tissue samples were lysed in 30 to
60 ml of NP-40 lysis buffer+protease inhibitors cocktail solution
(Roche) and the protein phase was collected after centrifugation.
Protein concentration was calculated using the Bradford Reagent
Kit (BioRad). Absorbance readings were measured at 595 nm
using a Beckman DU 530 Life Science UV/Visible spectropho-
tometer. After data collection, the concentration of the unknown
samples was determined based on standard absorbance value. The
protein samples were then exposed to SDS-polyacrilamide gel
electrophoresis, transferred to a Hybond C super nitrocellulose
membrane (GE Healthcare) and then blotted for the protein of
interest. Membranes were washed and Enhanced Chemilumines-
cence (ECL) detection system (GE Healthcare) was used for
visualization. The emitted fluorescence was detected using
Hyperfilm ECL (GE Healthcare) on SRX-101A x-ray developer.
Statistical Analysis
Biostatistical analyses were performed using the GraphPad
Prism software. Statistical comparisons were performed using
Student’s t-test or Pearsons Correlation coefficients.
Figure 1. Photographs of tissue blocks on microdissection slides at various stages of the procedure. N=normal colon, T = tumour,
A = adenoma. 1: Hematoxylin and eosin staining; 2: areas to be microdissected have been marked; 3: slide following microdissection of marked areas;
4: microdissected tissue following catapulting onto the inside of the eppedORF caps.
doi:10.1371/journal.pone.0098561.g001
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Results
Doxorubicin-induced DNA damage increases GAS5-
deriveded snoRNA expression in a p53 dependent
manner in colorectal cancer cell lines
We treated HCT116 p53WT and HCT116 p53KO cells with
doxorubicin in order to induce DNA damage, and used RT-qPCR
to measure the changes induced in the expression levels of various
small RNAs, particularly the GAS5-derived snoRNAs U44 and
U47. Doxorubicin treatment in HCT116 p53WT cell lines led to a
significant induction in the expression of the GAS5-derived
snoRNAs U44 (P,0.01) and U47 (P,0.01) when compared to
treatment with a control vehicle, but there was no significant
change in levels of the non-GAS5-associated snoRNA U19
(Figure 2) or the snRNA U6 that do not derive from the GAS5
locus when compared with GAPDH expression (data not shown).
Doxorubicin treatment did not significantly increase GAS5-derived
snoRNA expression in HCT116 p53KO cells (Figure 2), suggest-
ing that DNA damage induced the expression of the GAS5-derived
snoRNAs in a p53-dependent manner. Doxorubicin treatment of
HCT116 p53WT cells also significantly increased the expression of
miR-34a (P#0.006), used as a positive control, although the size of
the fold change varied depending on which small RNA was
selected to normalize expression levels to (Figure 2 & 3).
Following 24 hours of doxorubicin treatment, miR-34a expression
increased significantly by 2.8-fold and 2.6-fold (P#0.006 for both)
when levels were normalised to U6 and U19 respectively.
However, although still statistically significant, the fold-changes
in miR-34a expression levels were much smaller (1.9-fold; P,0.01)
when the GAS5-derived snoRNAs U44 and U47 were used for
normalisation (Figure 3). Similar differences were seen when p21
was used as a positive control (data not shown). Analysis of p53
chromatin immunoprecipitation sequencing (ChIP-seq) experi-
ments performed in HCT116 cells [29] indicates the presence of a
significant peak of p53 interaction in two independent experiments
involving p53 activation induced by Nutlin3 or 59fluorouracil
(5FU)), at the same position, approximately 800 bp away from the
GAS5 transcriptional start site (TSS), indicating that p53 directly
controls GAS5 transcription.
GAS5-derived snoRNA expression varies between normal
and malignant colorectal fresh non-microdissected tissue
in a p53-dependent manner
We found significant differences in the expression levels of the
GAS5-derived snoRNAs between paired samples of fresh frozen
normal colorectal tissue and colorectal tumour from the same
patient (P,0.01; Figure 4). snoRNA levels were significantly
higher in tumours compared to the corresponding normal
colorectal tissue in 85% of patient samples, but were significantly
lower in 15%. There was no significant difference in snRNA U6
Figure 2. DOX induces the expression of the GAS5-derived snoRNAs. Relative levels of (A) miR-34a, (B) U19 snoRNA, (C) U44 snoRNA and (D)
U47 snoRNA were measured by RT-qPCR in p53WT HCT116 cell lines and p53KO HCT116 cell lines treated with either doxorubicin (at a final
concentration 0.2 ug/ml) or vehicle for 24 hours. Levels were normalised to U6 snRNA levels and data are presented relative to the vehicle treated
cells 6 s.e.m (each of them performed in triplicate; Student’s t test: *P,0.01, **P#0.006).
doi:10.1371/journal.pone.0098561.g002
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levels between paired normal and tumour samples. Interestingly,
miR-34a levels were also significantly higher in patient tumour
samples when compared to their corresponding normal colorectal
tissue samples (P#0.0006; Figure 4). We then measured p53
expression levels in the paired normal colorectal tissue and
colorectal tumour samples using Western blotting (Figure 5A–C).
p53 levels were significantly higher in colorectal tumours
compared to their corresponding normal colorectal tissue samples
(P,0.01; Figure 5D).
Using the same samples, we calculated Pearson’s correlation
coefficients, comparing p53 expression levels with snoRNA U44
and U47 levels, to determine if any relationship existed between
GAS5-derived snoRNA levels and p53 in vivo in humans. We found
a strong positive correlation between p53 expression levels and the
levels of both snoRNA U44 (Pearson Correlation= 0.64; R2
linear = 0.41; P= 0.02) and snoRNA U47 (Pearson Correla-
tion= 0.69; R2 linear = 0.49; P = 0.01) in colorectal tumour
samples (Figure 6A). We also calculated Pearson’s correlation
coefficients to compare miR-34a expression levels with snoRNA
U44 and U47 levels, to determine if any relationship existed
between the levels of GAS5-derived snoRNAs and p53-regulated
miRNAs in humans. This was also performed to provide evidence
in support of the use of miR-34a as a surrogate marker for p53 in
this context for additional experiments using RNA derived from
microdissected FFPE tissue samples in which p53 levels were not
measurable by Western blotting. Interestingly, we found a strong
positive correlation between miR-34a expression levels and the
Figure 3. The GAS5-derived snoRNAs are not suitable housekeeping genes for use in experiments where DOX treatment. Relative
levels of miR-34a normalised to (A) U6 snRNA, (B) U47 snoRNA, (C) U44 snoRNA and (D) U19 snoRNA were measured by RT-qPCR in p53WT HCT116 cell
lines and p53KO HCT116 cell lines treated with either doxorubicin (at a final concentration 0.2 ug/ml) or vehicle for 24 hours. Data are presented
relative to the vehicle treated cells 6 s.e.m (each of them performed in triplicate; Student’s t test: *P,0.01, **P#0.006).
doi:10.1371/journal.pone.0098561.g003
Figure 4. Expression of the GAS5-derived snoRNAs is greater in
colorectal tumours than in benign colon tissue. A Box plot
comparing the relative expression levels of miR-34a, U44 snoRNA and
U47 snoRNA between paired colorectal tumour (T) and normal
colorectal (N) fresh frozen tissue samples. (Student’s t test *P,0.01,
***P#0.0006).
doi:10.1371/journal.pone.0098561.g004
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levels of both snoRNA U44 (Pearson Correlation= 0.73; R2
linear = 0.53; P= 0.001) and snoRNA U47 (Pearson Correla-
tion= 0.66; R2 linear = 0.43; P= 0.02) in colorectal tumour
samples (Figure 6B).
GAS5-derived snoRNA expression varies between normal,
pre-malignant and malignant microdissected FFPE
colorectal tissue and levels correlate with miR-34a
expression
There is much debate as to the accuracy of RNA and gene
expression studies that use non-microdissected tumour samples,
due to the possible effects that the cellular components of the
surrounding stroma can have on the levels of the measured
molecule. We therefore aimed to perform further experiments in
microdissected tissue samples to support the results above. We
collected 60 unpaired FFPE colorectal tissue samples consisting of
20 normal mucosa, 20 adenoma and 20 tumour specimens. We
microdissected the required portions after H&E staining, per-
formed RNA extraction and measured small RNA expression
levels by RT-qPCR (Figure 1). We found significantly higher
levels of miR-34a (P#0.006), snoRNA U44 (P#0.0005) and
snoRNA U47 (P#0.0005) in adenoma samples when compared
with normal mucosa samples (Figure 7A). Furthermore, the
expression of all 3 small RNAs was significantly higher in tumour
samples compared to adenoma or normal mucosa samples
(Figure 7A). In addition, p53 levels measured by immunohisto-
chemistry and given as a p53 score of 0–3, were higher in tumour
samples (80%= score of 3, 20%= score of 2) and adenoma
samples (50%= score of 3, 30% score of 2, 20% score of 1) than
normal tissue (100%= score of 0).
Using the same samples, we then calculated Pearson’s
correlation coefficients to compare miR-34a expression levels
and snoRNA U44 and U47 levels to determine if the relationship
demonstrated in non-microdissected samples between GAS5-
derived snoRNA levels and p53 (miR-34a being used here as a
surrogate marker for p53) was also seen in microdissected
colorectal tumours. We found a strong positive correlation
between miR-34a expression levels and the levels of both snoRNA
U44 (Pearson Correlation= 0.69; R2 linear = 0.47) and snoRNA
U47 (Pearson Correlation= 0.67; R2 linear = 0.45) in colorectal
tumour samples (Figure 7B).
The expression of GAS5-derived snoRNAs is not affected
in colorectal cancer cell lines in which DICER has been
knocked-down and therefore do not appear to be
processed by DICER
In view of the findings described in previous studies which
demonstrated that snoRNAs can be converted by DICER to
sdRNAs with miRNA-like functions it is possible that miRNA-like
molecules produced from GAS5 derived snoRNAs are involved in
the DNA damage response [3]. To investigate the possible
involvement of DICER in this process we assessed the effect of
Figure 5. A comparison of p53 expression levels between paired normal colorectal and colorectal tumour tissue samples. (A & B)
Western blot’s showing p53 levels in the first 10 normal colorectal (A) and colorectal tumour (B) tissue samples. GAPDH was used as a loading control.
(C) Column chart demonstrating the fold changes in p53 expression levels shown in the Western blots (A & B) normalised to GAPDH and calculated
using ImageJ software. (D) A box plot comparing the relative expression levels of p53 between all 25 paired colorectal tumour (T) and normal
colorectal (N) tissue samples (Student’s t test *P,0.01).
doi:10.1371/journal.pone.0098561.g005
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Figure 6. A positive correlation exists between GAS5-derived snoRNA levels and p53 expression in colorectal tissue samples. Graphs
showing Pearson correlation analyses of the relationship between (A) p53 levels or (B) miR-34a levels and the snoRNAs U44 and U47 in colorectal
tumour tissue samples (A & B).
doi:10.1371/journal.pone.0098561.g006
Figure 7. In microdissected colon samples the GAS5-derived snoRNAs are expressed more in malignant and pre-malignant tissue
than benign tissue and levels correlate with p53 expression. A, RT-qPCR was used to measure the relative expression levels of miR-34a,
snoRNA U44 and snoRNA U47 in microdissected human tissue samples corresponding to normal colorectal tissue (N), colorectal adenoma (A) and
colorectal tumours (T) (Student’s t test *P,0.05,**P#0.006,***P#0.0005). B, A Pearson’s correlation analysis was performed to determine the
relationship between miR-34a levels and the snoRNAs U44 and U47 in microdissected colorectal FFPE tumour tissue samples.
doi:10.1371/journal.pone.0098561.g007
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DICER knock-down on the expression of GAS5-derived snoRNAs
following DNA damage. To achieve this we used RT-qPCR to
compare changes in the expression of the snoRNAs U44 and U47
following doxorubicin treatment in the colorectal cancer cell lines
DLD1 and RKO in their wild-type (WT) form and in a form in
which DICER had been stably knocked down (KD). Interestingly,
we found that although DICER knock-down led to a statistically
significant reduction in miR-34a levels (P#0.006) in both DLD1
and RKO cell lines, as expected, there was no effect on the levels
of snoRNA U44 or snoRNA U47 (Figure 8), suggesting that the
function of the GAS5-derived snoRNAs in the p53-regulated
response to DNA damage did not involve their conversion into
sdRNAs with miRNA-like function.
Discussion
Our findings demonstrated a relationship between p53 activity
and the expression of the GAS5-derived snoRNAs in colorectal
cancer cell lines and human colorectal tissue. Furthermore, they
suggested that transcription of the GAS5 gene is directly regulated
by p53, although chromatin immunoprecipitation studies would
be required to confirm this. Although no functional studies have
been performed, these findings suggested an important role for the
GAS5-derived snoRNAs in the p53-regulated cellular response to
DNA damage and in p53-associated signalling pathways in human
colorectal tissue and colorectal cancer.
Until Chang et al. (2002) [30] first described the potential role of
snoRNAs in tumorigenesis, there had been little justification for
the systematic evaluation of the role of snoRNAs in this or any
other pathological condition. However data are accruing that link
a dysregulation in the expression of various snoRNAs to the
development of a number of malignancies [11,25,31,32]. As the
GAS5 gene hosts ten intronic snoRNAs and a lncRNA and has
been implicated in oncogenesis and the regulation of cell survival
and apoptosis [21–23], and given the well documented role for
p53 in the same processes, we aimed to further investigate the
relationship between p53 and the GAS5 snoRNAs to gain further
insight into their potential role in tumorigenesis. We found that, in
colorectal cancer cell lines, the GAS5-derived snoRNAs were
induced in a p53-dependent manner following DOX stimulated
DNA damage but that this affect was not lost when DICER was
functionally knocked down. This suggested that these snoRNAs
were not processed into sdRNAs with miRNA-like function, and
that their role in the DNA damage response did not require them
to be further processed in this manner. This indicates that these
snoRNAs might be involved in coordinating the p53-mediated
response through their role in regulating the ribosome. snoRNAs
are crucial for ribosomal function and the effective regulation of
translation [2] and p53 is a key mediator of ribosome biogenesis
especially in response to so-called nucleolar stress [33]. Further-
more, p53 has been shown to mediate the signaling link between
ribosome biogenesis and the cell cycle [34]. It seems logical
therefore that the GAS5-derived snoRNAs might be directly
induced by p53-mediated transcription following DNA damage in
order to ‘streamline’ the post-transcriptional maturation and
modification of rRNAs and to ensure a more efficient translation
of genes required to coordinate a response to such a stress. This
theory clearly requires further experimental evaluation not least by
proving that there is an increase in the localization of these
snoRNAs to the ribosome rather than an alternative cellular
compartment following DNA damage. It is possible that these
snoRNAs do act at a location other than the ribosome and that
they may have sdRNA type function but do not require DICER
processing to enable this. Whether these DNA damage induced
GAS5-derived snoRNAs simply function to accommodate an
increase in gene translation at the ribosome or whether they are
indeed processed to sdRNAs and have additional, independent
function, their effect on gene expression could be assessed through
over-expression experiments followed by gene profiling experi-
ments. This would enable us to determine their relevance in terms
of facilitating the p53-dependent response to DNA damage
through the post-transcriptional regulation of gene expression.
Following on from the cell line experiments, we further
demonstrated that a strong correlation existed between p53 levels
and GAS5-derived snoRNA expression in normal, pre-malignant
and malignant human tissue samples and that this might have
relevance in tumorigenesis. We found a strongly positive
correlation between p53 and the GAS5-derived snoRNAs in all
three tissue types and in both the micro-dissected FFPE samples
(where miR-34a was used as a surrogate marker for p53) and the
fresh non-micro-dissected samples. This provided further evidence
in support of a role for p53 in the induction of the GAS5-derived
snoRNAs and suggested a function for this process in vivo.
Interestingly U44 and U47 levels were found to be higher in
tumour samples than in normal or pre-malignant tissue which is
most likely the result of higher p53 expression in these tumours.
Remarkably, and some would argue paradoxically, p53 is
overexpressed in up to 50% of colorectal cancers and this has
been associated with a favourable prognosis in some studies
[35,36]. This paradox may be explained by the fact that in many
cases it is mutant rather than wild-type p53 that is overexpressed
and hence the effect on cell phenotype will vary based on the
function of the mutation variant [36–38]. On the other hand p53
is induced by oncogene expression as well as by DNA damage, so
it is possible that an oncogenic pathway that is driving that
particular tumour also leads to p53 induction. In fact, the survival
for patients with colorectal cancers expressing mutated p53, has
been shown to be significantly worse than for those patients with
tumours that expressed the wild-type protein and this was most
striking when mutations occurred outside the evolutionarily
conserved regions [38,39]. We did not specifically differentiate
Figure 8. The GAS5-derived snoRNAs are not processed by
DICER. Relative levels of U44 snoRNA (red), U47 snoRNA (blue) and
miR-34a (purple) were measured by RT-qPCR in DLD1 DICERWT cell lines,
DLD1 DICERKD cell lines, RKO DICERWT cell lines, RKO DICERKD cell lines
treated with either doxorubicin (at a final concentration 0.2 ug/ml) or
vehicle for 24 hours. Data are presented relative to the vehicle treated
corresponding cell lines (dotted line) 6 s.e.m (each of them performed
in triplicate; Student’s t test: *P,0.01, **P#0.006).
doi:10.1371/journal.pone.0098561.g008
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between mutant and wild-type p53 expression in our study and it
would be interesting to investigate in future work whether the
same correlation exists between mutant p53 and the GAS5-derived
snoRNAs in human tumour samples. It is likely that this will be
dependent on the specific p53 mutation as many do retain
transcriptional activity although often the gene set varies from that
regulated by wild-type p53. Interestingly, in our cell line work we
saw an induction in GAS5-derived snoRNA expression following
DOX treatment in the DLD1 cells which are known to contain the
R241F p53 mutant, and this demonstrated that this mutant form
of the protein was capable of transcriptionally activating the GAS5
gene. It would also have been interesting to correlate GAS5-
derived snoRNA levels with outcome in these patients, however as
these samples were all taken from patients with resectable Dukes
Stage A–C tumours there has not been a significant gap since their
diagnosis to accrue statistically meaningful results as the data are
too immature.
Finally, our experiments showed that the GAS5-derived
snoRNAs were not appropriate to be used as housekeeping genes
for normalising RT-qPCR experiments that used DOX to induce
DNA damage. We found that the relative expression of p53-
regulated miRNAs significantly differed depending on whether
GAS5-derived snoRNAs or alternative housekeeping genes such as
U6 snRNA or U19 snoRNA were used to normalise results. This
implies that the use of the GAS5-derived snoRNAs as normalising
genes in the context of DNA damage experiments would lead to
an inaccurate interpretation of the results, and suggests that the
snRNA U6 or snoRNA U19 would be more appropriate for
normalisation in such experiments.This is in keeping with the
findings of others who have shown that in experiments involving
human tumour samples, snoRNA expression was as variable as
miRNA expression and that normalising miRNA PCR expression
data to these snoRNAs introduced bias in associations between
miRNAs and outcome [18].
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